Physical activity and self-rerceived health among people aged 50 and over

El propósito del estudio es analizar los posibles efectos de la actividad física sobre la salud autopercibida. Para ello, se encuestó a 765 personas entre 50-70 años durante 2012 en España. Se utilizó el cuestionario internacional de actividad física (IPAQ) para estimar el equivalente metabólico de la tarea (MET) total y en cuatro ámbitos: trabajo, ocio, hogar y desplazamientos. La salud autopercibida se obtuvo de la escala visual analógica del EQ-5D-5L. Los resultados muestran que únicamente el gasto energético de actividad física en el tiempo de ocio incide positivamente en el nivel de salud percibido, el resto de ámbitos no tienen influencia significativa. Asimismo, la autopercepción de la salud es más negativa con mayor edad, menor nivel educativo y mayor frecuencia de uso de servicios sanitarios. En conclusión, la actividad física desarrollada en el tiempo libre podría plantearse como alternativa para mejorar la calidad de vida de los mayoresThe purpose of the study was to analyse possible related effects between exercise and self-perceived health among people over 50 years old. A survey was conducted in 2012 to 765 community-living subjects from Spain aged between 50 and 70 years. The survey includes the long version of the International Physical Activity Questionnaire (IPAQ) to estimate total physical activity/week in METS (Measure Activity in Metabolic Equivalents) and in four different domains: work, leisure, transport and domestic/gardening. Selfperceived health was measured using the Visual Analogic Scale of the EQ-5D- 5L. The results of the study show that only the level of physical activity developed in leisure time has a positive and statistically significant effect on self-perceived health, whilst the other domains of physical activity are non-significant. Additionally, age, lower educational level and a higher use of health-care services are negatively associated with self-perceived health. To sum up, leisure time physical activity could be an alternative to increase the quality of life of older peopl

Dealing with the health state ‘dead’ when using discrete choice experiments to obtain values for EQ-5D-5L heath states - Springer

__Abstract__ __Objective__ : To evaluate two different methods to obtain a dead (0)—full health (1) scale for EQ-5D-5L valuation studies when using discrete choice (DC) modeling. __Method__ : The study was carried out among 400 respondents from Barcelona who were representative of the Spanish population in terms of age, sex, and level of education. The DC design included 50 pairs of health states in five blocks. Participants were forced to choose between two EQ-5D-5L states (A and B). Two extra questions concerned whether A and B were considered worse than dead. Each participant performed ten choice exercises. In addition, values were collected using lead-time trade-off (lead-time TTO), for which 100 states in ten blocks were selected. Each participant performed five lead-time TTO exercises. These consisted of DC models offering the health state ‘dead’ as one of the choices—for which all participants’ responses were used (DCdead)—and a model that included only the responses of participants who chose at least one state as worse than dead (WTD) (DCWTD). The study also estimated DC models rescaled with lead-time TTO data and a lead-time TTO linear model. __Results__ : The DCdead and DCWTD models produced relatively similar results, although the coefficients in the DCdead model were slightly lower. The DC model rescaled with lead-time TTO data produced higher utility decrements. Lead-time TTO produced the highest utility decrements. __Conclusions__: The incorporation of the state ‘dead’ in the DC models produces results in concordance with DC models that do not include ‘dead’

A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study)

Background: Patient access to orphan medicinal products (OMPs) is limited and varies between countries, reimbursement decisions on OMPs are complex, and there is a need for more transparent processes to know which criteria should be considered to inform these decisions. This study aimed to determine the most relevant criteria for the reimbursement of OMPs in Spain, from a multi-stakeholder perspective, and using multicriteria decision analysis (MCDA). Methods: An MCDA was developed in 3 phases and included 28 stakeholders closely related to the field of rare diseases (6 physicians, 5 hospital pharmacists, 7 health economists, 4 patient representatives and 6 members from national and regional health authorities). Initially [phase A], a bibliographic review was conducted to identify the potential reimbursement criteria. Then, a reduced advisory board (8 members) proposed, selected, and defined the final list of criteria that could be relevant for reimbursement. A discrete choice experiment (DCE) [phase B] was developed to determine the relevance and relative importance weight of such criteria according to the stakeholders’ preferences by choosing between pairs of hypothetical financing scenarios. A multinomial logit model was fitted to analyze the DCE responses. Finally [phase C], the advisory board review the results using a deliberative process. Results: Thirteen criteria were selected, related to 4 dimensions: patient population, disease, treatment, and economic evaluation. Nine criteria were deemed relevant for decision-making and associated with a higher relative importance: Health-related quality of life (HRQL) (23.53%), treatment efficacy (14.64%), availability of treatment alternatives (13.51%), disease severity (12.62%), avoided costs (11.21%), age of target population (7.75%), safety (seriousness of adverse events) (4.72%), quality of evidence (3.82%) and size of target population (3.12%). The remaining criteria had a < 3% relative importance: economic burden of disease (2.50%), cost of treatment (1.73%), cost-effectiveness (0.83%) and safety (frequency of adverse events) (0.03%). Conclusion: The reimbursement of OMPs in Spain should be determined by its effect on patient’s HRQL, the extent of its therapeutic benefit from efficacy and the availability of other therapeutic options. Furthermore, the severity of the rare disease should also influence the decision along with the potential of the treatment to avoid associated costs

Pharmaceutical cost control in primary care: opinion and contributions by healthcare professionals

<p>Abstract</p> <p>Background</p> <p>Strategies adopted by health administrations and directed towards drug cost control in primary care (PC) can, according to earlier studies, generate tension between health administrators and healthcare professionals. This study collects and analyzes the opinions of general practitioners (GPs) regarding current cost control measures as well as their proposals for improving the effectiveness of these measures.</p> <p>Methods</p> <p>A qualitative exploratory study was carried out using 11 focus groups composed of GPs from the Spanish regions of Aragon, Catalonia and the Balearic Islands. A semi-structured guide was applied in obtaining the GPs' opinions. The transcripts of the dialogues were analyzed by two investigators who independently considered categorical and thematic content. The results were supervised by other members of the team, with overall responsibility assigned to the team leader.</p> <p>Results</p> <p>GPs are conscious of their public responsibility with respect to pharmaceutical cost, but highlight the need to spread responsibility for cost control among the different actors of the health system. They insist on implementing measures to improve the quality of prescriptions, avoiding mere quantitative evaluations of prescription costs. They also suggest moving towards the self-management of the pharmaceutical budget by each health centre itself, as a means to design personalized incentives to improve their outcomes. These proposals need to be considered by the health administration in order to pre-empt the feelings of injustice, impotence, frustration and lack of motivation that currently exist among GPs as a result of the implemented measures.</p> <p>Conclusion</p> <p>Future investigations should be oriented toward strategies that involve GPs in the planning and management of drug cost control mechanisms. The proposals in this study may be considered by the health administration as a means to move toward the rational use of drugs while avoiding concerns about injustice and feelings of impotence on the part of the GPs, which can lead to lack of interest in and disaffection with the current measures.</p

Economic evaluation of a mammography-based breast cancer screening programme in Spain.

The aim of the study was to perform a cost-effectiveness analysis of a breast cancer (BC) mammography screening programme, compared to a do-nothing alternative, in Spain. Screening consisted of a biennial mammography performed on all women 50-65 years old. A marginal analysis including women 45-49 years old was also performed. With the aid of a decision tree model, the numbers of BC cases diagnosed through screening, BC cases missed by screening and false-positive BC cases were calculated. Costs were calculated by feeding local data into Markovian models and the cost-effectiveness ratio calculation was performed in a computer spread sheet. A sensitivity analysis was also conducted. Results were presented in ECUs of 1993. The cost- effectiveness ratio per avoided death is 115,500 ECUs and per saved life year 7,300 ECUs. Including women 45-49 years old in the programme raises this ratio to 229,000 and 9,400 ECUs respectively. The sensitivity analysis showed the efficacy of mammography, compliance of the programme and screening costs to be the more sensitive variables

SELF-PERCEIVED HEALTH STATUS OF SCHIZOPHRENIC PATIENTS IN SPAIN: AN ANALYSIS OF GEOGRAPHICAL DIFFERENCES USING BAYESIAN APPROACH

Objectives. This paper explores the use of regression models for estimating health status of schizophrenic patients, from a Bayesian perspective. Our aims are: 1- To obtain a set of values of health states of the EQ-5D based on self-assessed health from a sample of schizophrenic patients. 2- To analyse the differences in the health status and in patients’ perceptions of their health status between four mental-health districts in Spain. Methods. We develop two linear models with dummy variables. The first model seeks to obtain an index of the health status of the patients using a VAS as a dependent variable and the different dimensions of EQ-5D as regressors. The second model allows to analyse the differences between the self-assessed health status in the different geographic areas and also the differences between the patients’ self-assessed health states, irrespective of their actual health state, in the different geographic areas. The analysis is done using Bayesian approach with Gibbs sampling (computer program WinBUGS 1.4). Data concerning self-assessed EQ-5D with VAS from four geographic areas of schizophrenic patients were obtained for the purposes of this analysis. Results. We obtained the health status index for this sample and analysed the differences for this index between the four geographic areas. Our study reveals variables that explain the differences in patients’ health status and differences in their health states assessment. We consider four possible scenarios.Schizophrenia, Bayesian analysis, effectiveness, quality of life, EQ-5D.

Paroxetine treatment for children and adolescents with anxiety disorders Paroxetina en los trastornos de ansiedad en niños y adolescentes

Background. Paroxetine has become an effectiveness treatment in anxiety disorders in adults. Despite the fact that this is an especially prevalent psychiatrist disorder in children and adolescents, there are very few studies in this population. This study examines the effectiveness of paroxetine in children and adolescents with anxiety disorders. Methodology. Fifteen children and adolescents with ICD-criteria for anxiety disorder were selected. Anxiety measurement was taken with STAI scale and was filled out before treatment and 6 months later (mean). We have used descriptive parameters and t Student test for the analysis of dependent samples. Statistic work was done with SPSS 8.0. Results. On first testing, the mean score for State Factor was 41.8 (ds: 5.9) and on second -after treatment- it was 24.66 (ds: 9.8). Trait Factor was 43.53 (ds: 8.27) on first testing and 25 (ds: 8.91) on second. These differences in mean scores for both State and Trait factors were significant (α=0.05, p